Jupiter Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Jupiter Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-28,535	Closed	-$3.69M	–	406
2018 Q2	$3.69M	Buy	+28,535	New	+$3.18M	0.03%	223
2017 Q1	–	Sell	-8,765	Closed	-$555K	–	442
2016 Q4	$555K	Sell	8,765 -27,493	-76%	-$1.73M	0.01%	252
2016 Q3	$2.31M	Buy	+36,258	New	+$2.66M	0.04%	213
2016 Q2	–	Sell	-98,054	Closed	-$6.55M	–	491
2016 Q1	$6.55M	Buy	+98,054	New	+$5.96M	0.13%	158

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jupiter Investment Management's LGND Position: Q3 2018 in Review

Jupiter Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 28,535 shares — an estimated $3.69M sold.

Jupiter Investment Management first reported a position in LGND in Q1 2016 and held it in 4 quarters. The position peaked at $6.55M in Q1 2016. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

Jupiter Investment Management reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Jupiter Investment Management sold 28,535 Ligand Pharmaceuticals shares in Q3 2018, an estimated $3.69M.
Jupiter Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 4 quarters.
Jupiter Investment Management's Ligand Pharmaceuticals position peaked at $6.55M in Q1 2016.
385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Jupiter Investment Management's 13F filing for Q3 2018, filed 17 Oct 2018.